Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
22 hedge funds and large institutions have $3.01M invested in Cyclo Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 5 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
43% more capital invested
Capital invested by funds: $2.1M → $3.01M (+$909K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 23 → 22 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$1.41M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.5K |
| 3 |
Renaissance Technologies
New York
|
+$36K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$85.9K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$35K |
| 3 |
BlackRock
New York
|
-$18.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$17K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$881 |
CYTH Hedge Fund Activity: Q1 2024 in Review
22 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q1 2024, worth a combined $3.01M — up 43% from $2.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CYTH and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 11 added.
The largest buyer was EPIQ Capital Group, opening a new position worth an estimated $1.41M. The largest seller was Citadel Advisors, exiting entirely with an estimated $85.9K sold.
- 22 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q1 2024, down from 23 in Q4 2023.
- Funds reported $3.01M of Cyclo Therapeutics, Inc. Common Stock stock for Q1 2024, up 43% quarter-over-quarter.
- 4 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q1 2024 and 5 closed out, a net change of -1 holder.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q1 2024 was EPIQ Capital Group, an estimated $1.41M added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q1 2024 was Citadel Advisors, an estimated $85.9K sold.
Based on aggregated 13F filings for Q1 2024.